As we approach the end of the year, Roche are providing an update to the Duchenne Community about their activities surrounding delandistrogene moxeparvovec (SRP-9001) for the treatment of Duchenne muscular dystrophy (DMD). Roche are developing this in partnership with Sarepta.
Please find the full update here:
Our amazing week in Levi, Lapland
